Biovail/Depomed’s Glumetza “Approvable” For Type II Diabetes
This article was originally published in The Pink Sheet Daily
Executive Summary
Approval of once-daily, extended-release metformin awaits completion of discussions on manufacturing specifications. FDA’s letter does not cite clinical, GMP or labeling issues, the companies say.